Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales? [PDF]
Ceftolozane/tazobactam is widely used against extended-spectrum β-lactamase (ESBL)-producing Enterobacterales, yet FDA-approved dosing relies on intermittent infusion and a fixed 2:1 ratio that assumes adequate β-lactamase inhibition. Tazobactam’s faster
Pai MP +7 more
europepmc +3 more sources
Stability of Two Reserve Antibiotics in Elastomeric Pumps: Ceftazidime-Avibactam and Ceftolozane-Tazobactam. [PDF]
Background/Objectives: Parenteral antibiotic therapy is indispensable in the treatment of several infections. The parenteral administration often leads to the need for prolonged hospitalization.
Erdmann J +3 more
europepmc +3 more sources
Ceftolozane/Tazobactam for Complex and Resistant Infections: Systematic Reviews of Comparative Efficacy Studies. [PDF]
Introduction: The emergence and spread of multidrug-resistant infections has resulted in significant clinical and economic burdens. To address these infections, novel therapy combinations are needed.
Martin-Loeches I +7 more
europepmc +2 more sources
Antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam, and comparators against Gram-negative pathogens collected in Arabian Gulf countries: SMART 2020-2024. [PDF]
ObjectivesTo investigate the in vitro susceptibility of recent clinical Enterobacterales and Pseudomonas aeruginosa isolates collected in the Arabian Gulf region to ceftolozane/tazobactam, imipenem/relebactam, and comparator antimicrobial agents ...
Wise MG +5 more
europepmc +2 more sources
Deciphering the emergence of mutations in Pseudomonas aeruginosa after ceftolozane/tazobactam treatment and evaluating therapeutic alternatives. [PDF]
Objectives Ceftolozane/tazobactam is a relevant option for treating multiresistant Pseudomonas aeruginosa, a major public health problem. Over a 14-month period, we studied the frequency of ceftolozane/tazobactam resistance development and mechanisms ...
Bientz L +13 more
europepmc +2 more sources
Trends in <i>Pseudomonas aeruginosa</i> In Vitro Susceptibility to Ceftolozane/Tazobactam in Latin America: SMART Surveillance Program, 2016-2024. [PDF]
Objectives: To describe annual trends in the susceptibility of clinical isolates of Pseudomonas aeruginosa from Latin America to ceftolozane/tazobactam.
Wise MG +6 more
europepmc +2 more sources
Assessment of in vitro antimicrobial activities of ceftolozane/tazobactam and ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa clinical isolates. [PDF]
Background Carbapenem resistant Pseudomonas aeruginosa (P. aeruginosa) is a global health concern that poses a challenge to treat in health care facilities.
Salem D +5 more
europepmc +2 more sources
: Objectives: Ceftolozane/tazobactam is a cephalosporin/β-lactamase inhibitor combination with activity against Gram-negative bacilli. Here we report the use of ceftolozane/tazobactam in Canada using a national registry. Methods: The CLEAR registry uses
George G. Zhanel +15 more
doaj +1 more source
Objective(s): The aim of this study was to conduct a meta-analysis to assess the clinical safety of ceftolozane-tazobactam for the treatment of acute bacterial infections in adult patients.
Li-Ting Wang +7 more
doaj +1 more source
Background: Ceftolozane-tazobactam is an emerging treatment for severe infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. However, limited data support its use in bacteremia treatment.
Hakeam A. Hakeam +10 more
doaj +1 more source

